• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>Annual and International Meeting of the Japanese Association for Animal Cell Technology >Production of Recombinant Human EPO and EPO/Fc Fusion Proteins by Chinese Hamster Ovary Cells
【24h】

Production of Recombinant Human EPO and EPO/Fc Fusion Proteins by Chinese Hamster Ovary Cells

机译：通过中国仓鼠卵巢细胞生产重组人EPO和EPO / FC融合蛋白

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Recombinant human erythropoietin (hEpo), the best-selling single drug in the US biotech drug market accounting for 10 dollar billion sales in 2006, is the most successful therapeutic agent empowered by the advent of recombinant DNA technology. hEpo isa glycoprotein hormone produced mainly by kidney cells whose production is stimulated by a reduction in the oxygen content into renal circulation. Its mechanism of action is based on the proliferation of erythroid progenitors in the bone marrow, resulting in replication and maturation towards functional erythrocytes. hEpo has widely been used to treat chronic kidney disease, anemia of cancer and anemia associated with chemotherapy. Carbohydrates attached to hEpo molecule have a central role modulatingits in vivo activity, particularly prolonging its serum half-life. In fact, a glyco-engineered version of hEpo trade name Darboepoetin~R presenting three-fold longer half-life enables dosing frequency reduction. Paradoxically, sialic acid carbohydrates play an inhibitory role on hEpo-receptor binding.
机译：重组人促红细胞生成素（HEPO），2006年美国生物技术药物市场占10美元销量的畅销单药，是重组DNA技术的出现赋予最成功的治疗剂。 HEPO ISA糖蛋白激素主要由肾细胞产生，其产生的产量通过氧含量的还原成肾循环。其作用机制基于骨髓中红细胞祖细胞的增殖，导致功能性红细胞的复制和成熟。 HEPO广泛用于治疗慢性肾病，患有化疗相关的癌症和贫血症。附着于HEPO分子的碳水化合物具有体内活性调节的中心作用，特别是延长其血清半衰期。事实上，HEPO商品名的GLYCO工程版DARBOEPOETIN〜R呈现三倍的半衰期，使得能量耗能减少。矛盾的是，唾液酸碳水化合物在Hepo受体结合上发挥抑制作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号